Canakinumab MAP in COVID-19 Pneumonia With CRS

Inclusion Criteria: * Age ≥ 18 years old; * Clinical diagnosis of SARS-CoV-2 virus by PCR, or by other approved diagnostic methodology, or, with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and COVID-19 test pending); * Hospitalized with COVID-19-induced pneumonia; * Elevated CRP or ferritin levels; * Body weight ≥ 40kg. Exclusion Criteria: * Eligible patients must not have a history of hypersensitivity to any drugs or metabolites of similar chemical classes as canakinumab; * On the day of canakinumab treatment initiation; treatment with biologic immunomodulators or immunosuppressant drugs, including but not limited to TNF inhibitors and anti-IL-17 agents. Immunomodulators (topical or inhaled) for asthma and atopic dermatitis are permitted as are systemic low-dose corticosteroids (e.g. ≤10 mg prednisone per day); * Use of tocilizumab within 3 weeks prior to dosing with canakinumab; * Suspected or known active bacterial, fungal, or parasitic infection (besides COVID-19); * Patients with significant neutropenia (ANC \<1000/mm3); * Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) prior to canakinumab dose.